Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hoth signs term sheet for Zylo's AEA-loaded Z-pods for CLE; later gains NA rights; Zylo regains rights

Executive Summary

Hoth Therapeutics Inc. and Zylo Therapeutics Inc. signed a non-binding term sheet to partner on the development of a treatment for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin disease, using Zylo's Z-pods sustained-release is a topical delivery system (also known as the Patchless Patch), to which Hoth could potentially get a license.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies